<![CDATA[Novo Nordisk Licenses Hengrui's Once-Weekly Oral GLP-1/GIP Dual Agonist HRS-1596 in Deal Worth Up to $2.6 Billion]]>

Tuesday, September 29, 2026View original

Read the full article on the original site.